Fosfomycin Trometamol Market REPORT OVERVIEW
- Request Free Sample to learn more about this report
The global fosfomycin trometamol market size was USD 31 million in 2021 and is projected to touch USD 42.74 million by 2031, at a CAGR of 3.1% during the forecast period.
The sudden spike in CAGR is attributable to demand returning to pre-pandemic levels once the pandemic is over.
Fosfomycin trometamol is a white or almost white crystalline powder, which is salty in taste, does not have an odor, and can dissolve in methanol, insoluble in chloroform, slightly soluble in ethanol, and soluble in water. It is an antibacterial or broad-spectrum disinfectant that targets gram-negative and gram-positive bacteria. It is a derivative of phosphonic acid. Phosphomycin is an antibiotic used in the treatment of the urinary tract. It is sold under the Monurol brand name, among others. Fosfomycin is good in vitro activity against uropathogenic such as Proteus mirabilis, Escherichia coli, Klebsiella pneumonia, and others.
The stability of fosfomycin trometamol remained stable over a period of time and is efficient enough to gain high concentration in urine by a single oral dose. Recent trials resulted that a single dose of the product contains the same bacteriological and clinical efficacy as 3-7 days regimen of norfloxacin, ciprofloxacin, nitrofurantoin, or cotrimoxazole in women suffering from uncomplicated lower urinary tract infections. Additionally, a single dose of the product has similar bacteriological efficacy to a 5-day cefuroxime axetil acid in pregnant women experiencing a lower UTI (Urinary Tract Infection).
COVID-19 Impact: Supply Chain Disturbed the Market Growth
Due to COVID-19's appearance, fewer patients were diagnosed with the condition, and treatment processes took longer. There was a decrease in demand for multiple medications. Due to the COVID-19 epidemic, major market participants saw their earnings rise slowly. The reallocation of healthcare resources harmed sales of medicines for the treatment of multiple infections for COVID-19 treatment, a decline in the number of patients seeking a diagnosis, and supply chain interruptions. The outbreak of the pandemic increased health care awareness among the population, which increased the use of fosfomycin trometamol in treatment of the urinary infections. The pandemic resulted in the breakdown of the supply chain, which affected the supply of the product in the global market.
LATEST TRENDS
"Rising Awareness about the Product Benefits to Aid Product Demand"
Steady results by taking one dose of this chemical prove its efficacy. This chemical has various benefits, such as one dose of fosfomycin trometamol will treat UTIs and prevent your body from getting affected by the infection again. The infected person can take medicine with or without food. It does not cause any harm on taking the medication without food. It can also penetrate biofilms. Additionally, it can eradicate clinically significant bacteria from the biofilms when mixed with other antibiotics.
Fosfomycin Trometamol Market Segmentation
- Request Free Sample to learn more about this report
- By Type Analysis
By type, the market is segmented into fosfomycin tromethamine granules and fosfomycin tromethamine powder.
- By Application Analysis
Based on application, the market is classified into common urinary tract infections and postoperative urinary tract infections.
DRIVING FACTORS
"Rising Incidences of UTIs Owing To the Population’s Changing Lifestyles"
The fosfomycin trometamol market growth is forecasted to be backed by the rising population, and their changing lifestyles are causing bladder infections and urinary tract infections. The use of fosfomycin trometamol in treating such infections is likely to surge fosfomycin trometamol market growth. A single oral dose of this chemical can almost cure the infection as it has antibacterial properties. The rising problem of antibacterial resistance leads to advanced interest in its recent development. This chemical is beneficial in the treatment of UTIs and complicated UTIs that include pyelonephritis. These factors are anticipated to drive growth.
"Online Pharmacies to Drive Growth in the Market"
The rising urbanization and technological advancements led to the launch of online pharmacies, which is forecasted to increase the fosfomycin trometamol market growth. Consumers can easily order medicines with one click after uploading the prescription. The availability of online pharmacies is projected to foster product growth in the market. The population is inclined toward using online services, and online pharmacies' availability turned out to be a driving factor for the market.
RESTRAINING FACTORS
"Side Effects Associated With the Product May Hamper Growth"
Higher consumption of the product may result in various health disorders such as headache, nausea, and other such issues. Higher consumption of this chemical cause’s nausea and vomiting, headache, and other such symptoms. Using fosfomycin trometamol requires high alertness, which may hamper the fosfomycin trometamol market growth. Higher consumption of this chemical may also result in weakness, runny nose, sore throat, and in women, it may cause menstrual pain, vaginal itching, or discharge.
Fosfomycin Trometamol Market REGIONAL INSIGHTS
- Request Free Sample to learn more about this report
"North America to Lead Owing to Rising Government Initiatives to Generate Health Awareness"
North America is projected to hold the maximum part of the fosfomycin trometamol market share owing to the rising government initiatives to generate awareness about the diagnosis and treatment of bladder infections.
Asia Pacific is forecasted to be the region holding the second-highest growth in the global market due to the high prevalence of UTIs in developing economies such as India, China, and Japan.
KEY INDUSTRY PLAYERS
"Key Players to Emphasize On Advanced Medicines Development to Grow in Market"
Important market participants work to implement tactics that will provide the company with long-term growth. The corporations place a strong emphasis on expanding their product line by introducing new items. Important players also concentrate on increasing their visibility through partnerships, agreements, joint ventures, expansions, and investments. The major players are well-represented on the international market. They also place a strong emphasis on expanding their regional distribution networks to acquire a competitive edge.
List of Market Players Profiled
- Zambon (Italy)
- Northeast Pharm (China)
- Hunan Huana Pharmaceuticals (China)
- Xunda Pharma (China)
- FarmaSino Pharmaceutical (China)
- Guilin Hwasun (China)
REPORT COVERAGE
The factors impacting market growth are closely monitored in the research. It includes a market forecast based on segment analysis, regional analysis, and motivating factors. The study also includes the variables that are projected to have an impact on the market expansion. To provide comprehensive insights into the market, a report on market essentials is created. The location and business tactics of the organization are also represented by a list of important market players. In order to give readers a quick overview of the competition, the competitive analysis is included in the report.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 31 Million in 2021 |
Market Size Value By |
US$ 42.74 Million by 2031 |
Growth Rate |
CAGR of 3.1% from 2021 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the fosfomycin trometamol market expected to touch by 2031?
Based on our research, the fosfomycin trometamol market is projected to touch USD 42.74 million by 2031.
-
What CAGR is the fosfomycin trometamol market expected to exhibit by 2031?
The fosfomycin trometamol market is expected to exhibit a CAGR of 3.1% by 2031.
-
What are the segments of the fosfomycin trometamol market?
By type, the fosfomycin trometamol market is segmented into fosfomycin tromethamine granules and fosfomycin tromethamine powder. Based on application, the market is classified into common urinary tract infections and postoperative urinary tract infections.
-
Which are the driving factors of the fosfomycin trometamol market?
Rising incidences of UTIs owing to the population’s changing lifestyles and online pharmacies to drive growth in the market are the factors driving the fosfomycin trometamol market.
-
Which are the top companies operating in the fosfomycin trometamol market?
Zambon, Northeast Pharm, Hunan Huana Pharmaceuticals, Xunda Pharma, FarmaSino Pharmaceutical, and Guilin Hwasun are the top companies operating in the fosfomycin trometamol market.